Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

作者：Paul Gerard Guy Richardson, Albert Oriol, Meral Beksaç, Anna Marina Liberati, Mónica Galli, Fredrik Hellem Schjesvold, Jindriska Lindsay, Katja Christina Weisel, Darrell J. White, Thierry T.F. Facon, Jesús F. San Miguel, Kazutaka Sunami, Peter O’Gorman, Pieter Sonneveld, Pawel J. Robak, С. В. Семочкин, Steve Schey, Xin Yu, Thomas Doerr, Amine Bensmaine, Tsvetan Nikolov Biyukov, Teresa Peluso, Mohamed H. Zaki, Kenneth Carl Anderson, Meletios Athanasios Dimopoulos, Niels Abildgaard, Howard L. Adler, Fevzi Altuntaş, Olga Meltem Akay, Bipinkumar Amin, Achilleas Anagnostopoulos, Larry Don Anderson, Pekka M. Anttila, Carla Araujo, Carlos Eduardo Arce-Lara, Yıldız Aydın, Supratik Basu, Ramakrishna Battini, Thaddeus Beeker, Lotfi Benboubker, Dina Ben‐Yehuda, Joan Bladé, Igor Wolfgang Blau, Ralph Vincent Boccia, Lillian P. Burke, Peter D. Byeff, Nicola Cascavilla, Michèle Cavo, Andrew Chantry, Yen Charles, Arvind Chaudhry, Alessandro Corso, Mark Coyne, Felipe de Arriba, Sosana Delimpasi, Pierre Desjardins, Binod Dhakal, Paolo Di Bartolomeo, Francesco Di Raimondo, Jan Dürig, Monika Martha Engelhardt, Martine Escoffre‐Barbe, Graça Esteves, Max Flogegård, Nashat Y. Gabrail, Barbara Gamberi, Mitchell A. Garrison, Julie Gay, Heinz Gisslinger, Hartmut Goldschmidt, Cristina Gonçalves, Laurent Gressot, Sebastian Grosicki, Wahid Tewfik Hanna, Patrick John Hayden, Maria Manuela Henriques Bernardo, Robert B. Hermann, Viran Holden, Kirsti Honkalehto, Marianne Terese Huben, John Huffman, Hannah M. Hunter, Marek Hus, Madan Jagasia, Sundar Jagganath, Murali Janakiram, Ishmael A. Jaiyesimi, Matthew W. Jenner, Cristina M. Joao, Peter R. E. Johnson, Artur Jurcyszyn, Sevgi Kalayoğlu Beşışık, Suman Kambhampati, Abraham Sebastian Kanate, Ìhsan Karadoǧan, Ali Khojasteh, Dean Kirkel, Mieczysław A. Komarnicki, Maria‐Theresa Krauth, Phillip Kuriakose, Alessandra Larocca, Birgitta Lauri, Xavier P Leleu, Paulo Lúcio, Mario Luppi, Silvia Mangiacavalli, Clara Mariette, Kosei Matsue, Ulf‐Henrik Mellqvist, Larisa Pavlovna Mendeleeva, Michael W. Meshad, Carole Brennan Miller, Ann M. Mohrbacher, Philippe Moreau, Anna Maria Morelli, Ercan Müldür, Anthony E. Naassan, Hareth Nahi, Rajesh Nair, Mike O'Dwyer, Şeniz Öngören Aydın, Thomas H. Openshaw, Timothy J. O’Rourke, Michael B. Osswald, Lindsay Overton, Asmin Pati, Michel Pavic, Brigitte Pegourié, Mustafa Pehlıvan, Ana Alfonso Piérola, Torben Plesner, Andrzej Pluta, Neil K. Rabin, Karthik Ramasamy, Alessandro Rambaldi, Paula Rodríguez, Christoph Röllig, Jacalyn M. Rosenblatt, Jonathan Z Rosenbluth, Morten Salomo, Olga Samoylova, Jose Sastre Moral, Hamdi I. A. Sati, Carmine Selleri, Salim Shafeek, Atsushi Shinagawa, Bethany G. Sleckman, Clayton A. Smith, Mehmet Sönmez, Chester Stone, Matthew J. Streetly, Kenshi Suzuki, Raymond Taetle, Agostino Tafuri, Naoki Takezako, Hava Üsküdar Teke, Mirja Vapaatalo, George Vassilopoulos, Amit K. Verma, Sarah I. Vidito, Luísa Viterbo, Filiz Vural, Xiang Wang, Münci Yağcı, Andrew Jenho Yee · 发表于：The Lancet Oncology · 年份：2019 · DOI：10.1016/s1470-2045(19)30152-4 · 被引用次数：390 · 研究领域：Multiple Myeloma Research and Treatments、Protein Degradation and Inhibitors、Cancer Treatment and Pharmacology